(Q74147656)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

S Malucchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

E Milano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

A Castello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Capobianco

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

R Mutani

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 July 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

95-100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Antibodies to beta-interferons in multiple sclerosis: can we neutralize the controversy?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Quantitation of neutralization of interferon by antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Site-specific mutagenesis of the human fibroblast interferon gene

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900182-X

7 January 2021

10.1016/S0162-3109(00)00182-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10936507%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference